Multiple myeloma (MM) is a B-cell malignancy in which abnormal, clonal plasma cells proliferate and accumulate in the bone marrow. These abnormal cells, referred to as myeloma cells, disrupt normal bone marrow function and invade bone. Myeloma cells produce and secrete significant quantities of monoclonal protein (M-protein) into the blood and/or urine.
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The clinical features of MM include hypercalcemia, renal failure, anemia, osteolytic bone lesions, and increased susceptibility to infections. 2 Nearly all MM cases are preceded by an asymptomatic, pre-malignant, condition known as monoclonal gammopathy of undetermined significance (MGUS) which may progress to a smoldering MM phase. 3 The disease course to symptomatic MM is driven by multiple genomic events within myeloma cells and abnormal interactions between myeloma cells and the bone marrow microenvironment. 2 Several chromosomal abnormalities have been identified in patients with MM and involve translocations, deletions, or amplifications.
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• MM is the second most common hematologic malignancy and accounts for approximately 13% of all hematologic cancers. 4 • Globally, an estimated 114,000 new cases of MM are diagnosed annually, with 80,000 deaths per year attributable to the disease. 4 • MM predominantly affects elderly people, and is most frequently diagnosed between the ages of 65-74 years. MM is more common in males and African Americans compared to females and Caucasians, respectively.
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• Overall, the 5-year survival among adults with MM is 48.5%. The treatment of MM has improved significantly over the last decade, resulting in many patients exhibiting a CR to front-line therapy.
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Unfortunately, the disease course of MM is characterized by a pattern of recurrent remissions and relapses. 1 Even after an initial CR, many patients inevitably relapse and MM remains an incurable disease. 10 While standardization and consensus on the role of MRD testing in MM is ongoing, the risk of relapse has shown to be correlated to MRD undetectable by conventional techniques. MRD refers to the persistence of small numbers of myeloma cells that remain after therapy and contribute to relapse and disease progression. 9, 11 In recent years, increasingly sensitive assays to detect MRD have been developed. 12 In a retrospective analysis of 3 clinical trials, 40% of patients with MM relapsed within 4 years after achieving a CR 
CR*
Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow aspirates sCR* CR plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry (κ/λ ratio ≤4:1 or ≥1:2 for κ and λ patients, respectively, after counting ≥100 plasma cells)
MRD-negative ‡
Absence of aberrant clonal plasma cells on bone marrow aspirate, ruled out by an assay † with a minimum sensitivity of 1 in 10 5 nucleated cells or higher (i.e. 10 -5 sensitivity)
Imaging-positive MRD-negative ‡ MRD negativity as defined by NGF or NGS plus disappearance of every area of increased tracer uptake found at baseline or a preceding PET/CT or decrease to less mediastinal blood pool SUV or decrease to less than that of surrounding normal tissue Sustained MRD-negative ‡ MRD negativity in the marrow (NGF or NGS, or both) and by imaging as defined above, confirmed minimum of 1 year apart. Subsequent evaluations can be used to further specify the duration of negativity (eg, MRD-negative at 5 years)
MRD in MM Summary
Relapses in MM could potentially reflect the presence of residual disease. Recently, technologic advances in molecular testing using MFC, ASO-PCR, and NGS, and imaging techniques such as PET-CT, have enabled the detection of myeloma cells with greater sensitivity.
11, 13
Ongoing studies will continue to define what level of MRD may be clinically relevant and how MRD assessment may inform treatment decision-making. 9 Additionally, an understanding of the heterogeneity of the disease biology may also be important in predicting the risk of relapse and sustainability of a response. Some patients who present with high-risk features at baseline may have persistent MRD despite achieving a CR, while patients with MGUS-like gene expression may experience better outcomes independent of CR status. 
